Supplementary Table 2 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Fields of Study & Subjects
CAR-T cell therapy research
Multiple Myeloma Research and Treatments
Immunotherapy and Immune Responses
Publication details
- Publication date
- 2 April 2026
- Language
- EN